In the Spotlight...

Epigenetic tuning of PD-1 expression improves exhausted T cell function and viral control

Weiss et al. used CRISPR–Cas9 genome editing to generate an exhaustion-specific PD-1 enhancer-deleted (EnhDel) mouse strain to interrogate its impact on PD-1 expression and CD8+ T cell state. Loss of ...

CXCR4 orchestrates the TOX-programmed exhausted phenotype of CD8+ T cells via JAK2/STAT3 pathway

Cao, Xu, Wei, and Peng et al. showed that CXCR4 was highly expressed in tumor-infiltrating CD8+ PD-1hi TEX cells in mice. Using the CXCR4 inhibitor plerixafor and WT or CXCR4 conditional-KO Tg mice, ...

Intratumoral radiation dose heterogeneity augments antitumor immunity in mice and primes responses to checkpoint blockade

Jagodinsky et al. used brachytherapy to deliver a spatially heterogeneous RT dose (2 to 30 gray) to syngeneic tumors in mice to reap the breadth of dose-dependent effects of RT on the TME. RT heteroge...

Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial

In an adaptive, window-of-opportunity phase II neoadjuvant trial in early breast cancer, Nederlof and Isaeva et al. report that 4 weeks of anti-PD-1 or anti-PD-1 + anti-CTLA-4 showed immune activation...

Previous Digests

A sweet spot in the spleen for immune checkpoint blockade responses

September 25, 2024

Immune checkpoint blockade unleashes powerful antitumor T cell responses, but exactly which T cell states are involved and from which anatomic locations they emerge are not fully understood. Investigating these topics, Morgan, Horton, Bhandarkar, et al. profiled T cells...

Flipping the script: reprogramming tumor cells into DCs

September 18, 2024

Type 1 conventional dendritic cells (cDC1s) are required for T cell-mediated tumor regression and response to immune checkpoint blockade (ICB) in cancer. However, current immunotherapy strategies are not focused on exploiting key aspects of cDC1 functionality in vivo, such...

Age is more than just a number in cancer immunotherapy

September 11, 2024

Age-related changes to the immune system contribute to increased cancer progression and resistance to immunotherapy in older patients. Investigating this, Georgiev and Han et al. recently found that tumors grew more rapidly in aged mice due to impaired cytotoxic...

Watch ACIR in action

In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.

Watch the 3-minute video explaining ACIR's mission and goal:

In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.

Watch the 6-minute segment on the story behind your favorite digest here:

About ACIR

ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.

Ed Fritsch

Ed Fritsch

Ute Burkhardt

Ute Burkhardt

Lauren Hitchings

Lauren Hitchings

Gaelle Lespinasse-Llambi

Gaelle Lespinasse-Llambi

Maartje Wouters

Maartje Wouters

Alex Najibi

Alex Najibi

Katherine J. Turner

Katherine J. Turner

Stan Wolf

Stan Wolf

Paula Hochman

Paula Hochman

Shishir Pant

Shishir Pant

Nathan Suek

Nathan Suek

Morgan Janes

Morgan Janes

Current Sponsors

Close Modal

Small change for you. Big change for us!

This Thanksgiving season, show your support for cancer research by donating your change.

In less than a minute, link your credit card with our partner RoundUp App.

Every purchase you make with that card will be rounded up and the change will be donated to ACIR.

All transactions are securely made through Stripe.